ClinicalTrials.gg
CompletedNCT04880668Updated Apr 1, 2022

Impact of Aerosol Box Use on Healthcare Provider Contamination

An interventional study of Aerosol Box (Splashguard) in Coronavirus, Covid19 and COVID-19 Acute Respiratory Distress Syndrome, sponsored by KidSIM Simulation Program. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-01.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's listed conditions name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by KidSIM Simulation Program · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in COVID-19 with a site in Canada — 24 open to participants now, 36 under way, 8 of them phase 3. COVID-19 · Canada.

Enrollment
96th of 200
122 · median 120
Started
2021
with 94 others
No phase
90 of 289
6 open now
Registered
175th of 289
by date

Among the 289 studies in COVID-19 with a site in Canada, this one is the 96th largest by enrollment of the 200 interventional ones that give a count, is one of 95 that started in 2021, is one of 90 with no phase, and was the 175th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

24 of the 289 studies in COVID-19 with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in COVID-19 with a site in Canada, or all of them as a file.
02

Study summary

Aerosol Generating Medical Procedures (AGMP) are procedures that have the potential to create tiny particles suspended in the air. These particles can contain germs such as viruses. The current Coronavirus Disease 2019 (COVID-19) pandemic is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients infected with SARS-CoV-2 experience unusually high rates of critical illness that needs advanced airway management and intensive care unit admission. Bag-valve-mask (BVM) ventilation, laryngeal mask airway insertion (LMA), and endotracheal Intubation (ETI) are common AGMP for critically ill COVID-19 patients, and may contribute to a high risk of infection amongst Health Care Workers (HCW). To lessen HCW risk during high-risk AGMPs, a device called an aerosol box has been developed to place over the head of the patient, shielding the provider's face from virus droplets suspended in the air.

The purpose of this research study is to better understand how particles disperse during AGMPs. The project team hopes what is learned from the project can help inform infection control measures. This could help make changes to the clinical environment and make it safer for HCW's. The investigators intend to investigate how an aerosol box performs in reducing contamination of HCW's who perform critical airway interventions.

Read the detailed description

The investigators plan to conduct a prospective, randomized controlled trial at four INSPIRE network sites (Alberta Children's Hospital, Ste. Justine Hospital, and Children's Hospital of Los Angeles and The Hospital for Sick Children). Simulation-based research confers the advantage of answering research questions without risk of harm to HCPs or patients, which is particularly important when studying a disease process with high mortality. Ethics approval has been submitted at all sites. Two participants will form an airway team, recruited to play the roles of airway provider and airway assistant for management of a simulated, critically ill COVID-19 patient. Participants will be randomized by team into either the control arm (i.e. no aerosol box) or the intervention arm (i.e. use of aerosol box). Following randomization, all participants will view a short video orienting them to the simulated clinical environment. Intervention arm teams will view an additional 5-minute video orienting them to the use of the aerosol box, and receive up to 15 minutes of hands-on training (see below for details). After orientation, teams will participate in three sequential simulation scenarios. The order of scenario delivery will be randomized to eliminate scenario order as a potential confounder. The location and nature of equipment, temperature and humidity within the resuscitation room will be standardized across all sites. A Laerdal Resusci-Anne manikin will be used as a simulated patient.

The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway. As our study includes only one airway assistant, the two holes that are not in use will be sealed shut during the study. The airway assistant will be directed to stand in a standardized position, to the immediate right of the airway provider. In a prior study, an aerosol box placed over the head of an adult volunteer demonstrated air leaks out of the box during exhalation and coughing that could be eliminated with the addition of a plastic drape. For this reason, the investigators have incorporated a plastic drape extending from the top of the box down to the patient's chest to prevent spread of aerosols. In another experiment, the addition of continuous wall suction to the aerosol box setup resulted in significantly decreased airborne particle exposure (for the airway provider) compared to aerosol box use without suction. Given that wall suction is ready available and accessible in most acute care areas, the aerosol box setup will include wall suction, with suction tubing running into the aerosol box at one point along the bottom of the box near the head of the patient. Wall suction will be set at 200 mmHg, which is consistent with the pressure used in prior studies to generate a negative airflow of approximately 50 L/min.

All participants (i.e. airway provider and airway assistant) randomized to the intervention arm will receive aerosol box training. A 5-minute video will orient participants to the design of the aerosol box and include expert-modeled demonstration of strategies for optimal BVM ventilation, ETI, and LMA insertion using an aerosol box with a 2-person airway team. The training video will be shot in English and French to permit viewing across study sites in Alberta, Ontario and Quebec. After viewing the video, participants will work in pairs to practice all three procedures for a maximum of 15 minutes, providing them opportunity to coordinate their movements to optimize efficiency. After each procedure, the participants will receive feedback from a local airway and aerosol box expert (i.e. site investigator).

The amount of aersolization that occurs in real patients is highly variable and dependent upon many factors (e.g. viral load, method of aerosolization, etc.), making it impossible to exactly replicate aerosolization of SARS-CoV-2 virus in the simulated environment. In this study, the investigators aim to create a model of aerosolization by standardizing various aspects of care (e.g. ventilation pressures, particle size and volume deposited, lung compliance), thus allowing us to make comparisons between different contexts (ie. aerosol box vs no box; BVM vs. LMA vs. ETI). To visualize aerosolization of particles, the study team will adapt methodology successfully utilized in studies evaluating aerosolization during airway management. GloGerm©™(Glo Germ Company, Moab, UT, USA) is a nontoxic, invisible fluorescent resin marker that illuminates when exposed to ultraviolet (UV) light. The SARS-CoV-2 virus requires a water and mucus envelope to spread, with the size of these virus-containing envelopes varying from larger droplets (>60 µm) to smaller airborne particles or infectious droplet nuclei (5-10 µm diameter). With a particle size of approximately 5 µm, Glo Germ™ represents a reasonable surrogate for aerosolized SARS-CoV-2. AGMPs can generate aerosols in two ways: by mechanically inducing and dispersing aerosols, or by inducing the patient to cough to produce aerosols. This study focuses on aerosols mechanically induced by three commonly performed AGMPs: BVM ventilation, LMA insertion, and ETI. Glo Germ™(0.5 mL) will be applied to the oropharynx and trachea of the manikin to simulate secretions. Glo Germ™ will be aerosolized from the mechanical pressures and airflow associated with bagging, or from manipulation of the airway, which is consistent with the current understanding of aerosolization mechanics in AGMPs. Participants will titrate ventilation pressures to 20 cm H2O peak inspiratory pressure, and 5-6 cm H2O peak end expiratory pressure using a digital pressure manometer that provides real-time feedback. Pilot work done using the methods (and ventilation pressures) described above resulted in contamination on the hands, torso, face shield, and feet of airway providers during BVM ventilation. This suggests these methods are sufficient to produce a measurable amount of Glo Germ™ particles during manual ventilation.

Prior to each scenario, all participants will donn personal protective equipment (PPE), consisting of: a gown, nitrile gloves, face shield, googles, and a N95 respirator. The brand, type and size of gowns and face shields will be standardized across all sites. PPE will be donned with a partner, guided by a standardized PPE donning checklist, and checked by a research assistant prior to the scenarios. All scenarios are 5 minutes in duration and tightly standardized by using a scenario template with pre-scripted patient progression. Intervention arm teams will use the aerosol box in all three scenarios while control arm teams will not use the aerosol box. At the end of the entire session, participants will receive an educational debriefing to discuss performance issues, infection control measures, and technical skills using a blended-method approach to debriefing. Doffing will occur in conjunction with a PPE partner, and guided by a standardized PPE doffing checklist to ensure consistency.

Scenario A: BVM Ventilation - depicts an adolescent patient with suspected COVID-19, presenting with progressive respiratory distress and desaturation. Participants will be directed to initiate BVM ventilation with a HEPA filter as per guidelines for managing COVID-19 pediatric patients. Aerosolization of particles occurs during manual ventilation, while the mask is on the patient's face. The scenario will last a total of 5 minutes.

Scenario B: ETI - depicts an adult patient with suspected COVID-19, presenting with progressive respiratory failure requiring intubation. In this scenario, providers will be advised by the team leader not to initiate BVM ventilation, which is consistent with AHA guidelines for adult COVID-19 patients requiring airway management. Participants will be directed to sedate, paralyze and intubate the patient using a videolaryngoscope (e.g. GlideScopeTM), and provide manual ventilation after intubation with a HEPA filter in place. The scenario will last a maximum of 5 minutes, or until the patient is successfully intubated, whichever is longer.

Scenario C: LMA Insertion - depicts the same patient as in Scenario B. In this scenario, providers will be advised by the team leader to insert an LMA. Participants will be directed to sedate, paralyze and intubate the patient, and provide manual ventilation after LMA insertion with a HEPA filter in place. The scenario will last a maximum of 5 minutes, or until the patient is successfully intubated, whichever is longer.

Data collection will occur immediately after each scenario, prior to and after doffing of PPE (see outcomes below). After data collection, the resuscitation room and airway trainer will be cleaned. Clean PPE will be provided for all participants for each scenario. These measures will ensure there is no incremental accumulation of GloGermTM particles from prior scenarios. All scenarios will be videotaped from a birds-eye view angle at the head of the bed. Video from the video laryngoscopy device will be captured during Scenario B.

Randomization will occur at the level of the team, stratified by study site and sex of the airway provider (to ensure equal distribution of sex in both arms), and conducted in blocks of 4 to ensure an even distribution of teams across study arms. Randomization packages will be prepared at a central study side using a web-based random number generator. Sequentially numbered recruitment packages provided for each site will contain sealed opaque envelopes (i.e. one envelope per study arm) with study arm assignments and unique identifier codes for participants.

Sample size estimation is based on primary outcome measure. Given the paucity of quantitative research in this area, the investigators propose a sample of 60 teams (120 participants) in total, or 30 teams (60 participants) per study arm. As each team will receive repeated measures (i.e. 3 scenarios), this sample size permits detection of a medium effect size (Cohen's d = 0.65), with a significance level of 0.05, a power of 0.8, and a high intra-cluster correlation coefficient (rho = 0.7) to make a conservative estimation. Accounting for missing data due to technical issues, the investigators will recruit one extra team per study group at each site. Therefore, the total sample size will be 66 teams (132 participants).

03

Conditions studied

  • Coronavirus
  • Covid19
  • COVID-19 Acute Respiratory Distress Syndrome

Browse trials for

Keywords

  • simulation
  • AGMP
  • aerosol generating medical procedure
  • intubation
  • bag valve mask ventilation
  • laryngeal mask airway
04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's enrollment of 122 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

KidSIM Simulation Program is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Airway Provider):

  • Healthcare provider from inpatient unit, intensive care unit, operating room unit and/or emergency department
  • Attending physician or fellow in emergency medicine, intensive care, pediatrics, or anesthesia
  • Adult or Pediatric Advanced Life Support certification

Inclusion Criteria (Airway Assistant)

  • Healthcare provider from inpatient unit, intensive care unit, operating room unit and/or emergency department
  • Attending physician, resident, fellow, nurse or respiratory therapist
  • Adult or Pediatric Advanced Life Support certification.

Exclusion Criteria:

  • Decline to provide
  • Unable to perform tasks required of the role due to physical limitations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • No intervention
    Control - No aerosol box

    Participants will perform the AGMP without an aerosol box

  • Experimental
    Intervention - Aerosol box

    Participants will perform the AGMP with an aerosol box

    Device: Aerosol Box (Splashguard)

Interventions

  • DeviceAerosol Box (Splashguard)

    The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.

07

What researchers measure

Primary outcomes

  1. Change in Integrated Density (Pre vs Post Doffing)

    Integrated density of HCP contamination, quantified from digital photos of GloGerm™ deposited on the airway team members pre and post-doffing.

    Time frame: Immediately after each procedure (BVM, ETI, LMA)

  2. Change in Area of contamination (Pre vs Post Doffing)

    Quantified from digital photos of GloGerm™ deposited on the airway team members pre and post-doffing.

    Time frame: Immediately after each procedure (BVM, ETI, LMA)

Secondary outcomes

  1. Time to task completion

    time to successful intubation or LMA insertion (captured by video review by 2 trained and calibrated raters)

    Time frame: Immediately after ETI and LMA procedures

  2. First pass success rate

    first pass success rate for ETI and LMA insertion (captured by video review by 2 trained and calibrated raters)

    Time frame: Immediately after ETI and LMA procedures

  3. Number of healthcare providers contaminated

    Number of healthcare providers contaminated

    Time frame: Immediately after each procedure (BVM, ETI, LMA)

  4. Number of different body parts contaminated

    Number of different body parts contaminated

    Time frame: Immediately after each procedure (BVM, ETI, LMA)

  5. Environmental Contamination

    integrated density of environmental contamination, captured by taking a photo of the room in standardized conditions

    Time frame: Immediately after each procedure (BVM, ETI, LMA)

  6. Provider Workload

    Provider workload as measured by NASA TLX survey, rated on a scale of 0-20, with 20 being maximum workload for each element

    Time frame: Immediately after each procedure (BVM, ETI, LMA)

  7. Quality of intubation performance

    Quality of intubation performance (captured by video review of both video laryngoscopy and video from within the room) assessed using a previously published intubation checklist; rated on a scale of 0 to 41, with 41 being perfect performance

    Time frame: Immediately after ETI

  8. Provider opinions on aerosol box

    pros and cons of using aerosol box, captured by questionnaire completed by both participants (multiple choice and open field question types)

    Time frame: Immediately after all 3 procedures are completed

08

Study locations

4 sites
  • Department of Emergency Medicine, Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • KidSIM-ASPIRE Simulation Research Program Alberta Children's Hospital
    Calgary, Alberta, Canada
  • Department of Pediatrics, The Hospital for Sick Children
    Toronto, Ontario, Canada
  • Department of Pediatrics, CHU Sainte-Justine
    Montreal, Quebec, Canada
09

References and documents

Individual participant data

Plan to share: No — No plan to share data with other researcher. Potential sharing may be possible upon individual request with justification.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2021, 6 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 11, 2021
StartActual
Jun 11, 2021
Primary completionActual
Dec 16, 2021
CompletionActual
Dec 16, 2021
Last update
Apr 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04880668
Lead sponsor
KidSIM Simulation Program
Collaborators
International Network for Simulation-based Pediatric Innovation, Research and Education, Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Jun 11, 2021
Primary completion
Dec 16, 2021
Completion
Dec 16, 2021
Last update
Apr 1, 2022

Study contacts

Adam Cheng, MD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion